<?xml version="1.0" encoding="UTF-8"?>
<p id="para0052">Aside from the aforementioned approaches, Genexine Inc. is exploring a new vaccine via utilizing the Hyleukin-7 platform technology 
 <xref rid="bib0162" ref-type="bibr">[162]</xref>. Such a platform may improve the immune responses fusing IL-7 with hyFc, aiming to hybridize IgD and IgG4 for the long-term effect of Fc fusion proteins 
 <xref rid="bib0163" ref-type="bibr">[163]</xref>, 
 <xref rid="bib0164" ref-type="bibr">[164]</xref>, 
 <xref rid="bib0165" ref-type="bibr">[165]</xref>. Specifically, IgD possesses a flexible hinge structure and can maximize the biological activity 
 <xref rid="bib0153" ref-type="bibr">[153</xref>,
 <xref rid="bib0154" ref-type="bibr">154]</xref>. IgG4 possesses an unexposed junction site that mitigates immunogenicity via preventing antibody-dependent cellular cytotoxicity 
 <xref rid="bib0155" ref-type="bibr">[155</xref>,
 <xref rid="bib0156" ref-type="bibr">156]</xref>. This corporation reported enhanced vaccine efficacy, lung T cell accumulation, and plasmacytoid dendritic cell growth after Fc-fused IL-7 treatment in the virus infection models 
 <xref rid="bib0166" ref-type="bibr">[166]</xref>.
</p>
